COVID-19 Vaccine Market

COVID-19 Vaccine Market (Vaccine Type: mRNA, Viral Vector Vaccines (Adenovirus Vaccines, Inactivated Virus Vaccines, and Others), and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031

COVID-19 Vaccine Market Outlook 2031

  • The industry was valued at US$ 92.6 Bn in 2021
  • It is projected to record CAGR of -13.6 from 2022 to 2031 to reach more than US$ 9.9 Bn by the end of 2031

Analysts’ Viewpoint

Emergence of new variants of virus and rise in government support for the development and distribution of COVID-19 vaccines are estimated to fuel market statistics. Increase in demand for booster shots to maintain immunity against new variants of the virus is creating growth opportunities for market players. However, the COVID-19 vaccine market has presently entered a period of stabilization, owing to the rapid decline in cases and increase in rate of vaccination around the globe. COVID-19 vaccine market demand has declined significantly, as more than 70% of the global population has already been vaccinated to date.

In the long term, the industry may need to consider strategies for maintaining demand for vaccines, such as promoting the benefits of coronavirus vaccination for herd immunity, or developing new vaccines for other infectious diseases. Overall, the COVID-19 vaccine market has been highly profitable for pharmaceutical companies. Leading players should focus on distribution and inventory management and explore coronavirus vaccine market opportunities.

Covid 19 Vaccine Market

Market Introduction

COVID-19 vaccines are medical products designed to protect individuals from the novel coronavirus (SARS-CoV-2) that causes COVID-19. The vaccines work by teaching the immune system to recognize and fight the virus, thereby reducing the risk of severe illness or death from COVID-19. Several different COVID-19 vaccines have been developed and authorized for emergency use around the world, including vaccines developed by Pfizer-BioNTech, Moderna, AstraZeneca-Oxford, Johnson & Johnson, and others. mRNA and viral vector vaccines are the major types of COVID vaccines. These vaccines use different technologies, such as messenger RNA (mRNA) and adenovirus vectors, to instruct the body to produce an immune response against the virus. Vaccines have undergone rigorous testing in clinical trials to ensure their safety and efficacy. Trials have shown that vaccines are highly effective at preventing severe illness and death caused by COVID-19, and they have been authorized for use by regulatory bodies around the world. Vaccines are being distributed globally to protect as many people as possible from the virus and to help bring an end to the pandemic.

The emergence of New Variants of Virus

The emergence of new variants of the virus is one of the significant COVID-19 vaccine market growth drivers. These variants have the potential to be more transmissible and/or more resistant to current vaccines, which means that people who have been vaccinated may not be fully protected against them. This is a significant concern for public health officials and healthcare providers, as it could lead to a resurgence of the pandemic. To address this issue, people who have been vaccinated may need to get booster shots or updated versions of the vaccine to maintain immunity against these new variants. This is projected to fuel COVID-19 vaccine market development in the near future.

Rise in Investment in the Development and Distribution of Vaccines by Several Governments and Pharmaceutical Companies

Governments have invested large amounts of money in the development, testing, and distribution of vaccines to combat the pandemic. This investment has been crucial in speeding up the process of vaccine development, and ensuring that vaccines are made available to the public as quickly as possible.

Pharmaceutical companies also invested heavily in the development and distribution of vaccines. These companies have invested in R&D to create new vaccines and booster shots, and have also invested in manufacturing facilities to produce these vaccines on a large scale.

Furthermore, the demand for vaccines is expected to remain high in the near future, as people are getting vaccinated to prevent the resurgence of COVID-19.

Increase in Demand for Highly Effective mRNA Vaccines

mRNA vaccines have been proven to be highly effective at triggering an immune response, with some achieving efficacy rates upwards of 95%. These vaccines are relatively easy to develop compared to other types of vaccines. mRNA vaccines do not require the use of a live virus, as is the case with viral vector vaccines. This means that mRNA vaccines can be produced faster and with fewer resources. As a result, mRNA vaccines are gaining popularity among end-users.

mRNA vaccines also have the advantage of being relatively stable, meaning they can be stored at a lower temperature than other types of COVID-19 vaccines. This makes them easier to transport, store, and distribute.

Purchase, Distribution, and Administration of Vaccine Doses by Government Entities

In terms of distribution channel, the government entities segment is anticipated to lead the global COVID-19 vaccine industry during the forecast period.

Governments are usually the primary providers of healthcare services in several countries. Moreover, government entities often have the resources and infrastructure to support large-scale vaccine distribution campaigns. Furthermore, governments are often responsible for the purchase, distribution, and administration of vaccine doses. Government bodies ensure that there is an adequate supply of vaccines for their citizens.

Government entities have made considerable investments to ramp up production and distribution of COVID-19 vaccines, and have coordinated with private companies and other entities to ensure that their citizens have access to the necessary doses. Several governments have created special programs to ensure that vulnerable populations have access to the vaccine. All these factors are positively impacting the COVID-19 vaccine market share.

Larger Population and Availability of Vaccines for Above 18 Age Group

In terms of age group, the global COVID-19 vaccine market has been segmented into 12 to 18 and above 18. The above 18 segment is likely to dominate the market during the forecast period. The adult population is more likely to get vaccinated than the younger population in the near future, as adults can easily understand the importance of vaccination.

The adult population is much larger than the younger population. According to the World Population Review of 2020, the population of adults aged 18 and above is around 4.6 billion, whereas the population of children aged 12 to 18 is around 1.2 billion. Vaccines for individuals 12 to 18 years of age are not readily available. This drives the segment.

In the U.S., the Pfizer-BioNTech vaccine was the first vaccine to be approved, and it was only approved for people aged 16 and above. Likewise, the Moderna vaccine was approved for those aged 18 and above.

Regional Outlook of Global COVID-19 Vaccine Market

North America is projected to dominate the global market during the forecast period. Increase in presence of major pharmaceutical companies and advanced healthcare infrastructure in the U.S. is fueling market progress.

Europe is expected to be the second-largest regional market for COVID-19 vaccines in the next few years, owing to the presence of well-developed healthcare infrastructure and rise in availability of skilled resources to manufacture vaccines.

In Asia Pacific, increase in government support to develop COVID-19 vaccines and the presence of the world's largest vaccine manufacturers, such as the Serum Institute of India and BioNTech, are driving the market.

Analysis of Key Players in Global COVID-19 Vaccine Business

Companies operating in the global market are focusing on strategies such as product launches, divestiture, mergers & acquisitions (M&A), and partnerships to strengthen their position in the market.

Some of the prominent COVID-19 vaccine manufacturers are Pfizer-BioNTech, Moderna, AstraZeneca, Johnson & Johnson, Sinovac, Sinopharm, Bharat Biotech, Serum Institute of India, Novavax, Gamaleya Research Institute, CanSino Biologics, CureVac, GlaxoSmithKline and Sanofi-GSK.

Key Developments

  • In August 2022, FDA expanded the age indication of Novavax COVID-19 vaccine. This vaccine is presently available for individuals 12 years of age and older.
  • In August 2021, Pfizer and BioNTech announced the launch of their mRNA-based vaccine for the prevention of COVID-19 in individuals 12 years and older
  • In May 2021, Moderna announced the launch of its mRNA-based vaccine for the prevention of COVID-19 in individuals 12 years and older

The global COVID-19 vaccine market report profiles key players based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.

Market Snapshot

Attribute

Detail

Market Size Value in 2021

US$ 92.6 Bn

Market Forecast Value in 2031

More than US$ 9.9 Bn

Compound Annual Growth Rate (CAGR)

-13.6%

Forecast Period

2022–2031

Historical Data Available for

2017–2021

Quantitative Units

US$ Bn for Value

Market Analysis

It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, and parent industry overview.

Competition Landscape

  • Market share analysis/ranking by company (2021)
  • Company profiles section includes overview, product portfolio, key subsidiaries or distributors, strategy & recent developments, and key financials

Format

Electronic (PDF) + Excel

Market Segmentation

  • Vaccine Type
    • mRNA
    • Viral Vector Vaccines
      • Adenovirus Vaccines
      • Inactivated Virus Vaccines
      • Others
    • Others
  • Age Group
    • 12 to 18
    • Above 18
  • Distribution Channel
    • Government Entities
    • Hospitals and Clinics
    • Others

Regions Covered

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Countries Covered

  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • China
  • India
  • Japan
  • Australia & New Zealand
  • Brazil
  • Mexico
  • GCC Countries
  • South Africa

Companies Profiled

  • Pfizer-BioNTech
  • Moderna
  • AstraZeneca
  • Johnson & Johnson
  • Sinovac
  • Sinopharm
  • Bharat Biotech
  • Serum Institute of India
  • Novavax
  • Gamaleya Research Institute
  • CanSino Biologics
  • CureVac
  • GlaxoSmithKline
  • Sanofi-GSK Other Prominent Players

Customization Scope

Available upon request

Pricing

Available upon request

Frequently Asked Questions

How big was the global COVID-19 vaccine market in 2021?

The global market was valued at US$ 92.6 Bn in 2021

How big will it be by 2031?

It is projected to reach more than US$ 9.9 Bn by 2031

What will be the CAGR during the forecast period (2022–2031)?

The CAGR is anticipated to be -13.6% from 2022 to 2031

Which are the prominent trends that affect business growth?

Emergence of new variants of the virus and increase in investment in development and distribution of vaccines by several governments and pharmaceutical companies

What was the share of the leading segment in 2021?

The mRNA segment held the largest share in 2021

Which region is likely to account for major share?

North America is likely to account for major share during the forecast period

Who are the prominent players?

Pfizer-BioNTech, Moderna, AstraZeneca, Johnson & Johnson, Sinovac, Sinopharm, Bharat Biotech, Serum Institute of India, Novavax, Gamaleya Research Institute, CanSino Biologics, CureVac, GlaxoSmithKline, and Sanofi-GSK.

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global COVID-19 Vaccine Market

4. Market Overview

    4.1. Introduction

        4.1.1. COVID-19 vaccine Definition

        4.1.2. Industry Evolution/Developments

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global COVID-19 Vaccine Market Analysis and Forecast, 2017–2031

        4.4.1. Market Revenue Projections (US$ Mn)

5. Market Outlook

    5.1. Disease incidence and prevalence across the globe

    5.2. Analysis of COVID-19 vaccination across the globe

    5.3. Regulatory scenario across the globe/key countries

6. Global COVID-19 Vaccine Market Analysis and Forecast, by Vaccine Type

    6.1. Introduction & Definition

    6.2. Key Findings/Developments

    6.3. Market Value Forecast, by Vaccine Type, 2017–2031

        6.3.1. mRNA

        6.3.2. Viral Vector Vaccines

            6.3.2.1. Inactivated Virus Vaccines

            6.3.2.2. Adenovirus Vaccines

            6.3.2.3. Others

        6.3.3. Others

    6.4. Market Attractiveness, by Vaccine Type

7. Global COVID-19 Vaccine Market Analysis and Forecast, by Age Group

    7.1. Introduction & Definition

    7.2. Key Findings/Developments

    7.3. Market Value Forecast, by Age Group, 2017–2031

        7.3.1. 12 to 18

        7.3.2. Above 18

    7.4. Market Attractiveness, by Age Group

8. Global COVID-19 Vaccine Market Analysis and Forecast, by Distribution Channel

    8.1. Introduction & Definition

    8.2. Key Findings/Developments

    8.3. Market Value Forecast, by Distribution Channel, 2017–2031

        8.3.1. Government Entities

        8.3.2. Hospitals and Clinics

        8.3.3. Others

    8.4. Market Attractiveness, by Distribution Channel

9. Global COVID-19 Vaccine Market Analysis and Forecast, by Region

    9.1. Key Findings

    9.2. Market Value Forecast, by Region

        9.2.1. North America

        9.2.2. Europe

        9.2.3. Asia Pacific

        9.2.4. Latin America

        9.2.5. Middle East & Africa

    9.3. Market Attractiveness, by Country/Region

10. North America COVID-19 Vaccine Market Analysis and Forecast

    10.1. Introduction

        10.1.1. Key Findings

    10.2. Market Value Forecast, by Vaccine Type, 2017–2031

        10.2.1. mRNA

        10.2.2. Viral Vector Vaccines

            10.2.2.1. Inactivated Virus Vaccines

            10.2.2.2. Adenovirus Vaccines

            10.2.2.3. Others

        10.2.3. Others

    10.3. Market Value Forecast, by Age Group, 2017–2031

        10.3.1. 12 to 18

        10.3.2. Above 18

    10.4. Market Value Forecast, by Distribution Channel, 2017–2031

        10.4.1. Government Entities

        10.4.2. Hospitals and Clinics

        10.4.3. Others

    10.5. Market Value Forecast, by Country, 2017–2031

        10.5.1. U.S.

        10.5.2. Canada

    10.6. Market Attractiveness Analysis

        10.6.1. By Vaccine Type

        10.6.2. By Age Group

        10.6.3. By Distribution Channel

        10.6.4. By Country

11. Europe COVID-19 Vaccine Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. Market Value Forecast, by Vaccine Type , 2017–2031

        11.2.1. mRNA

        11.2.2. Viral Vector Vaccines

            11.2.2.1. Viral Vector Vaccines

            11.2.2.2. Adenovirus Vaccines

            11.2.2.3. Others

        11.2.3. Others

    11.3. Market Value Forecast, by Age Group, 2017–2031

        11.3.1. 12 to 18

        11.3.2. Above 18

    11.4. Market Value Forecast, by Distribution Channel, 2017–2031

        11.4.1. Government Entities

        11.4.2. Hospitals and Clinics

        11.4.3. Others

    11.5. Market Value Forecast, by Country, 2017–2031

        11.5.1. U.K.

        11.5.2. Germany

        11.5.3. France

        11.5.4. Italy

        11.5.5. Spain

        11.5.6. Rest of Europe

    11.6. Market Attractiveness Analysis

        11.6.1. By Vaccine Type

        11.6.2. By Age Group

        11.6.3. By Distribution Channel

        11.6.4. By Country

12. Asia Pacific COVID-19 Vaccine Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Market Value Forecast, by Vaccine Type, 2017–2031

        12.2.1. mRNA

        12.2.2. Viral Vector Vaccines

            12.2.2.1. Inactivated Virus Vaccines

            12.2.2.2. Adenovirus Vaccines

            12.2.2.3. Others

        12.2.3. Others

    12.3. Market Value Forecast, by Age Group, 2017–2031

        12.3.1. 12 to 18

        12.3.2. Above 18

    12.4. Market Value Forecast, by Distribution Channel, 2017–2031

        12.4.1. Government Entities

        12.4.2. Hospitals and Clinics

        12.4.3. Others

    12.5. Market Value Forecast, by Country, 2017–2031

        12.5.1. China

        12.5.2. Japan

        12.5.3. India

        12.5.4. Rest of Asia Pacific

    12.6. Market Attractiveness Analysis

        12.6.1. By Vaccine Type

        12.6.2. By Age Group

        12.6.3. By Distribution Channel

        12.6.4. By Country

13. Latin America COVID-19 Vaccine Market Analysis and Forecast

    13.1. Introduction

        13.1.1. Key Findings

    13.2. Market Value Forecast, by Vaccine Type, 2017–2031

        13.2.1. mRNA

        13.2.2. Viral Vector Vaccines

            13.2.2.1. Inactivated Virus Vaccines

            13.2.2.2. Adenovirus Vaccines

            13.2.2.3. Others

        13.2.3. Others

    13.3. Market Value Forecast, by Age Group, 2017–2031

        13.3.1. 12 to 18

        13.3.2. Above 18

    13.4. Market Value Forecast, by Distribution Channel, 2017–2031

        13.4.1. Government Entities

        13.4.2. Hospitals and Clinics

        13.4.3. Others

    13.5. Market Value Forecast, by Country, 2017–2031

        13.5.1. Brazil

        13.5.2. Mexico

        13.5.3. Rest of Latin America

    13.6. Market Attractiveness Analysis

        13.6.1. By Vaccine Type

        13.6.2. By Age Group

        13.6.3. By Distribution Channel

        13.6.4. By Country

14. Middle East & Africa COVID-19 Vaccine Market Analysis and Forecast

    14.1. Introduction

        14.1.1. Key Findings

    14.2. Market Value Forecast, by Vaccine Type, 2017–2031

        14.2.1. mRNA

           14.2.1.1. Inactivated Virus Vaccines

           14.2.1.2. Adenovirus Vaccines

           14.2.1.3. Others

        14.2.2. Viral Vector Vaccines

        14.2.3. Others

    14.3. Market Value Forecast, by Age Group, 2017–2031

        14.3.1. 12 to 18

        14.3.2. Above 18

    14.4. Market Value Forecast, by Distribution Channel, 2017–2031

        14.4.1. Government Entities

        14.4.2. Hospitals and Clinics

        14.4.3. Others

    14.5. Market Value Forecast, by Country, 2017–2031

        14.5.1. GCC countries

        14.5.2. South Africa

        14.5.3. Rest of Middle East & Africa

    14.6. Market Attractiveness Analysis

        14.6.1. By Vaccine Type

        14.6.2. By Age Group

        14.6.3. By Distribution Channel

        14.6.4. By Country

15. Competition Landscape

    15.1. Market Player – Competition Matrix (by Tier and Size of Companies)

    15.2. Market Share Analysis by Company (2021)

    15.3. Company Profiles

        15.3.1. Pfizer-BioNTech

            15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.1.2. Vaccine Type Portfolio

            15.3.1.3. Financial Overview

            15.3.1.4. SWOT Analysis

            15.3.1.5. Strategic Overview

        15.3.2. Moderna

            15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.2.2. Vaccine Type Portfolio

            15.3.2.3. Financial Overview

            15.3.2.4. SWOT Analysis

            15.3.2.5. Strategic Overview

        15.3.3. AstraZeneca

            15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.3.2. Vaccine Type Portfolio

            15.3.3.3. Financial Overview

            15.3.3.4. SWOT Analysis

            15.3.3.5. Strategic Overview

        15.3.4. Johnson & Johnson

            15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.4.2. Vaccine Type Portfolio

            15.3.4.3. Financial Overview

            15.3.4.4. SWOT Analysis

            15.3.4.5. Strategic Overview

        15.3.5. Sinovac

            15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.5.2. Vaccine Type Portfolio

            15.3.5.3. Financial Overview

            15.3.5.4. SWOT Analysis

            15.3.5.5. Strategic Overview

        15.3.6. Sinopharm

            15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.6.2. Vaccine Type Portfolio

            15.3.6.3. Financial Overview

            15.3.6.4. SWOT Analysis

            15.3.6.5. Strategic Overview

        15.3.7. Bharat Biotech

            15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.7.2. Vaccine Type Portfolio

            15.3.7.3. Financial Overview

            15.3.7.4. SWOT Analysis

            15.3.7.5. Strategic Overview

        15.3.8. Serum Institute of India

            15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.8.2. Vaccine Type Portfolio

            15.3.8.3. Financial Overview

            15.3.8.4. SWOT Analysis

            15.3.8.5. Strategic Overview

        15.3.9. Novavax

            15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.9.2. Vaccine Type Portfolio

            15.3.9.3. Financial Overview

            15.3.9.4. SWOT Analysis

            15.3.9.5. Strategic Overview

        15.3.10. Gamaleya Research Institute

            15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.10.2. Vaccine Type Portfolio

            15.3.10.3. Financial Overview

            15.3.10.4. SWOT Analysis

            15.3.10.5. Strategic Overview

        15.3.11. CanSino Biologics

            15.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.11.2. Vaccine Type Portfolio

            15.3.11.3. Financial Overview

            15.3.11.4. SWOT Analysis

            15.3.11.5. Strategic Overview

        15.3.12. CureVac

            15.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.12.2. Vaccine Type Portfolio

            15.3.12.3. Financial Overview

            15.3.12.4. SWOT Analysis

            15.3.12.5. Strategic Overview

        15.3.13. GlaxoSmithKline

            15.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.13.2. Vaccine Type Portfolio

            15.3.13.3. Financial Overview

            15.3.13.4. SWOT Analysis

            15.3.13.5. Strategic Overview

        15.3.14. Sanofi-GSK

            15.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.14.2. Vaccine Type Portfolio

            15.3.14.3. Financial Overview

            15.3.14.4. SWOT Analysis

            15.3.14.5. Strategic Overview

List of Tables

Table 01: Global COVID-19 Vaccine Market Value (US$ Mn) Forecast, by Vaccine Type, 2017–2031

Table 02: Global COVID-19 Vaccine Market Value (US$ Mn) Forecast, by mRNA, 2017–2031

Table 03: Global COVID-19 Vaccine Market Value (US$ Mn) Forecast, by Viral Vector Vaccines, 2017–2031

Table 04: Global COVID-19 Vaccine Market Value (US$ Mn) Forecast, by Age Group, 2017–2031

Table 05: Global COVID-19 Vaccine Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 06: Global COVID-19 Vaccine Market Value (US$ Mn) Forecast, by Region, 2017–2031

Table 07: North America COVID-19 Vaccine Market Value (US$ Mn) Forecast, by Vaccine Type, 2017–2031

Table 08: North America COVID-19 Vaccine Market Value (US$ Mn) Forecast, by mRNA, 2017–2031

Table 09: North America COVID-19 Vaccine Market Value (US$ Mn) Forecast, by Viral Vector Vaccines, 2017–2031

Table 10: North America COVID-19 Vaccine Market Value (US$ Mn) Forecast, by Age Group, 2017–2031

Table 11: North America COVID-19 Vaccine Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 12: North America COVID-19 Vaccine Market Value (US$ Mn) Forecast, by Country, 2017–2031

Table 13: Europe COVID-19 Vaccine Market Value (US$ Mn) Forecast, by Vaccine Type , 2017–2031

Table 14: Europe COVID-19 Vaccine Market Value (US$ Mn) Forecast, by mRNA, 2017–2031

Table 15: Europe COVID-19 Vaccine Market Value (US$ Mn) Forecast, by Viral Vector Vaccines, 2017–2031

Table 16: Europe COVID-19 Vaccine Market Value (US$ Mn) Forecast, by Age Group, 2017–2031

Table 17: Europe COVID-19 Vaccine Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 18: Europe COVID-19 Vaccine Market Value (US$ Mn) Forecast, by Country/Sub-Region, 2017–2031

Table 19: Asia Pacific COVID-19 Vaccine Market Value (US$ Mn) Forecast, by Vaccine Type, 2017–2031

Table 20: Asia Pacific COVID-19 Vaccine Market Value (US$ Mn) Forecast, by mRNA, 2017–2031

Table 21: Asia Pacific COVID-19 Vaccine Market Value (US$ Mn) Forecast, by Viral Vector Vaccines, 2017–2031

Table 22: Asia Pacific COVID-19 Vaccine Market Value (US$ Mn) Forecast, by Age Group, 2017–2031

Table 23: Asia Pacific COVID-19 Vaccine Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 24: Asia Pacific COVID-19 Vaccine Market Value (US$ Mn) Forecast, by Country/Sub-Region, 2017–2031

Table 25: Latin America COVID-19 Vaccine Market Value (US$ Mn) Forecast, by Vaccine Type, 2017–2031

Table 26: Latin America COVID-19 Vaccine Market Value (US$ Mn) Forecast, by mRNA, 2017–2031

Table 27: Latin America COVID-19 Vaccine Market Value (US$ Mn) Forecast, by Viral Vector Vaccines, 2017–2031

Table 28: Latin America COVID-19 Vaccine Market Value (US$ Mn) Forecast, by Age Group, 2017–2031

Table 29: Latin America COVID-19 Vaccine Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 30: Latin America COVID-19 Vaccine Market Value (US$ Mn) Forecast, by Country/Sub-Region, 2017–2031

Table 31: Middle East & Africa COVID-19 Vaccine Market Value (US$ Mn) Forecast, by Vaccine Type, 2017–2031

Table 32: Middle East & Africa COVID-19 Vaccine Market Value (US$ Mn) Forecast, by mRNA, 2017–2031

Table 33: Middle East & Africa COVID-19 Vaccine Market Value (US$ Mn) Forecast, by Viral Vector Vaccines, 2017–2031

Table 34: Middle East & Africa COVID-19 Vaccine Market Value (US$ Mn) Forecast, by Age Group, 2017–2031

Table 35: Middle East & Africa COVID-19 Vaccine Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 36: Middle East & Africa COVID-19 Vaccine Market Value (US$ Mn) Forecast, by Country/Sub-Region, 2017–2031

List of Figures

Figure 01: Global COVID-19 Vaccine Market

Figure 02: Global COVID-19 Vaccine Market Size (US$ Mn) Forecast, 2017–2031

Figure 03: Market Value Share, by Vaccine Type (2021)

Figure 04: Market Value Share, by Age Group (2021)

Figure 05: Market Value Share, by Distribution Channel (2021)

Figure 06: Market Value Share, by Region (2021)

Figure 07: Global COVID-19 Vaccine Market Value Share, by Vaccine Type, 2021 and 2031

Figure 08 Global COVID-19 Vaccine Market Attractiveness, by Vaccine Type , 2021–2031

Figure 09: Global COVID-19 Vaccine Market Value Share, by Age Group, 2021 and 2031

Figure 10: Global COVID-19 Vaccine Market Attractiveness, by Age Group, 2021–2031

Figure 11: Global COVID-19 Vaccine Market Value Share, by Distribution Channel, 2021 and 2031

Figure 12: Global COVID-19 Vaccine Market Attractiveness, by Distribution Channel, 2021–2031

Figure 13: Global COVID-19 Vaccine Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2031

Figure 14: Global COVID-19 Vaccine Market Value Share, by Region, 2021–2031

Figure 15: Global COVID-19 Vaccine Market Attractiveness, by Region, 2021–2031

Figure 16: North America COVID-19 Vaccine Market Value Share, by Vaccine Type, 2021 and 2031

Figure 17: North America COVID-19 Vaccine Market Attractiveness, by Vaccine Type , 2021–2031

Figure 18: North America COVID-19 Vaccine Market Value Share, by Age Group, 2021 and 2031

Figure 19: North America COVID-19 Vaccine Market Attractiveness, by Age Group, 2021–2031

Figure 20: North America COVID-19 Vaccine Market Value Share, by Distribution Channel, 2021 and 2031

Figure 21: North America COVID-19 Vaccine Market Attractiveness, by Distribution Channel, 2021–2031

Figure 22: North America COVID-19 Vaccine Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2031

Figure 23: North America COVID-19 Vaccine Market Value Share, by Country, 2021–2031

Figure 24: North America COVID-19 Vaccine Market Attractiveness, by Country, 2021–2031

Figure 25: Europe COVID-19 Vaccine Market Value Share, by Vaccine Type, 2021 and 2031

Figure 26: Europe COVID-19 Vaccine Market Attractiveness, by Vaccine Type , 2021–2031

Figure 27: Europe COVID-19 Vaccine Market Value Share, by Age Group, 2021 and 2031

Figure 28: Europe COVID-19 Vaccine Market Attractiveness, by Age Group, 2021–2031

Figure 29: Europe COVID-19 Vaccine Market Value Share, by Distribution Channel, 2021 and 2031

Figure 30: Europe COVID-19 Vaccine Market Attractiveness, by Distribution Channel, 2021–2031

Figure 31: Europe COVID-19 Vaccine Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2031

Figure 32: Europe COVID-19 Vaccine Market Value Share, by Country/Sub-Region, 2021–2031

Figure 33: Europe COVID-19 Vaccine Market Attractiveness, by Country/Sub-Region, 2021–2031

Figure 34: Asia Pacific COVID-19 Vaccine Market Value Share, by Vaccine Type, 2021 and 2031

Figure 35: Asia Pacific COVID-19 Vaccine Market Attractiveness, by Vaccine Type , 2021–2031

Figure 36: Asia Pacific COVID-19 Vaccine Market Value Share, by Age Group, 2021 and 2031

Figure 37: Asia Pacific COVID-19 Vaccine Market Attractiveness, by Age Group, 2021–2031

Figure 38: Asia Pacific COVID-19 Vaccine Market Value Share, by Distribution Channel, 2021 and 2031

Figure 39: Asia Pacific COVID-19 Vaccine Market Attractiveness, by Distribution Channel, 2021–2031

Figure 40: Asia Pacific COVID-19 Vaccine Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2031

Figure 41: Asia Pacific COVID-19 Vaccine Market Value Share, by Country/Sub-Region, 2021–2031

Figure 42: Asia Pacific COVID-19 Vaccine Market Attractiveness, by Country/Sub-Region, 2021–2031

Figure 43: Latin America COVID-19 Vaccine Market Value Share, by Vaccine Type, 2021 and 2031

Figure 44: Latin America COVID-19 Vaccine Market Attractiveness, by Vaccine Type , 2021–2031

Figure 45: Latin America COVID-19 Vaccine Market Value Share, by Age Group, 2021 and 2031

Figure 46: Latin America COVID-19 Vaccine Market Attractiveness, by Age Group, 2021–2031

Figure 47: Latin America COVID-19 Vaccine Market Value Share, by Distribution Channel, 2021 and 2031

Figure 48: Latin America COVID-19 Vaccine Market Attractiveness, by Distribution Channel, 2021–2031

Figure 49: Latin America COVID-19 Vaccine Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2031

Figure 50: Latin America COVID-19 Vaccine Market Value Share, by Country/Sub-Region, 2021–2031

Figure 51: Latin America COVID-19 Vaccine Market Attractiveness, by Country/Sub-Region, 2021–2031

Figure 52: Middle East & Africa COVID-19 Vaccine Market Value Share, by Vaccine Type, 2021 and 2031

Figure 53: Middle East & Africa COVID-19 Vaccine Market Attractiveness, by Vaccine Type, 2021–2031

Figure 54: Middle East & Africa COVID-19 Vaccine Market Value Share, by Age Group, 2021 and 2031

Figure 55: Middle East & Africa COVID-19 Vaccine Market Attractiveness, by Age Group, 2021–2031

Figure 56: Middle East & Africa COVID-19 Vaccine Market Value Share, by Distribution Channel, 2021 and 2031

Figure 57: Middle East & Africa COVID-19 Vaccine Market Attractiveness, by Distribution Channel, 2021–2031

Figure 58: Middle East & Africa COVID-19 Vaccine Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2031

Figure 59: Middle East & Africa COVID-19 Vaccine Market Value Share, by Country/Sub-Region, 2021–2031

Figure 60: Middle East & Africa COVID-19 Vaccine Market Attractiveness, by Country/Sub-Region, 2021–2031

Figure 61: Global COVID-19 Vaccine Market Share Analysis, by Company, 2021 (Estimated)

Figure 62: Global COVID-19 Vaccine Market Performance, by Company, 2021

Figure 63: Competition Matrix

Copyright © Transparency Market Research, Inc. All Rights reserved